AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
CureVac NV (NASDAQ:CVAC)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 4.66 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 12.360/2.215 |
| EBITDA (in USD) | -268.898M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -1.31 |
| Total Assets (in USD) | 788.899M |
|---|---|
| Total Liabilities (in USD) | 271.532M |
| Revenue TTM (in USD) | 59.002M |
| Cash (in USD) | 402.784M |
| Market Cap (in USD) | 823.203 M |
| Revenue Per Share TTM | 0.263 |
| Gross Profit TTM (in USD) | -91.549M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
CureVac NV
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Employees: 999
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D. | CEO, Member of Management Board & MD | 1970 |
| 2. | Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 1975 |
| 3. | Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board | 1972 |
| 4. | Dr. Igor Splawski M.Sc., Ph.D. | Chief Scientific Officer & Member of Management Board | 1969 |
| 5. | Dr. Antony Blanc Ph.D. | MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board | 1970 |
| 6. | Mr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 1965 |
| 7. | Dr. Sarah Fakih | VP Corp. Communications & Investor Relations | NA |
| 8. | Mr. Marco Rau L.L.M., Ph.D. | Gen. Counsel | NA |
| 9. | Mr. Thorsten Schuller | Head of Corp. Communications | NA |
| 10. | Slavica Stevanovic-Heck | Head of HR | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -249.155M | -412.498M | -129.8M | -100.125M | -71.131M |
| Minority Interest | - | - | - | - | - |
| Net Income | -249.029M | -411.716M | -129.074M | -99.873M | -71.241M |
| Selling General Administrative | 88.994M | 87.201M | 45.029M | 42.183M | 20.415M |
| Gross Profit | -116.573M | -135.205M | 34.727M | -10.567M | -4.873M |
| Reconciled Depreciation | 23.741M | 15.674M | 10.671M | 7.164M | 3.781M |
| Ebit | -249.457M | -412.263M | -124.002M | -99.498M | -70.856M |
| Ebitda | -223.102M | -386.486M | -109.8M | -91.501M | -67.075M |
| Depreciation And Amortization | 26.355M | 25.777M | 14.202M | 7.997M | 3.781M |
| Operating Income | -249.457M | -412.263M | -124.002M | -99.498M | -72.824M |
| Other Operating Expenses | 318.272M | 515.253M | 158.7M | 116.913M | 85.695M |
| Interest Expense | 3.707M | 10.338M | 22.103M | 1.46M | 0.275M |
| Tax Provision | -0.126M | -0.782M | -0.726M | -0.252M | 0.11M |
| Interest Income | 4.009M | 10.103M | 2.07M | 0.833M | 1.968M |
| Net Interest Income | 0.302M | -0.235M | -20M | -0.627M | 1.693M |
| Income Tax Expense | -0.126M | -0.782M | -0.726M | -0.252M | 0.11M |
| Total Revenue | 67.42M | 102.99M | 48.9M | 17.416M | 12.871M |
| Total Operating Expenses | 134.279M | 277.058M | 158.7M | 88.93M | 67.951M |
| Cost Of Revenue | 183.993M | 238.195M | 14.173M | 27.983M | 17.744M |
| Total Other Income Expense Net | 0.302M | -0.235M | -5.798M | -0.627M | 1.693M |
| Net Income From Continuing Ops | -249.029M | -411.716M | -129.8M | -99.873M | -71.241M |
| Net Income Applicable To Common Shares | - | -411.716M | -129.122M | -99.873M | -71.241M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 788.899M | 860.472M | 1158.242M | 1511.356M | 130.62M |
| Intangible Assets | 15.882M | 19.315M | 13.238M | 14.146M | 5.698M |
| Other Current Assets | 15.25M | 5.345M | 49.244M | 48.289M | 1.15M |
| Total Liab | 271.532M | 327.219M | 469.766M | 800.009M | 173.422M |
| Total Stockholder Equity | 517.367M | 533.253M | 688.476M | 711.347M | -42.802M |
| Other Current Liab | 90.514M | 46.219M | 176.252M | 68.78M | 13.27M |
| Common Stock | 26.901M | 23.4M | 22.454M | 21.655M | 0.727M |
| Capital Stock | 26.879M | 23.4M | 22.454M | 21.655M | 0.727M |
| Retained Earnings | -1567.272M | -1305.814M | -1056.785M | -645.069M | -515.947M |
| Good Will | 12.473M | 12.463M | - | - | - |
| Other Assets | 0M | 2.974M | 5.557M | 7.455M | 6.343M |
| Cash | 402.784M | 495.797M | 811.464M | 1322.593M | 30.684M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 186.543M | 156.225M | 357.734M | 247.622M | 28.086M |
| Current Deferred Revenue | 44.617M | 36.78M | 55.75M | 157.985M | 7.481M |
| Net Debt | -360.925M | -453.711M | -782.572M | -1292.506M | 48.464M |
| Short Term Debt | 5.009M | 4.98M | 3.469M | 3.234M | 2.004M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 41.858M | 42.086M | 28.892M | 30.087M | 79.148M |
| Other Stockholder Equity | 2057.805M | -1.481M | -5.817M | 1358.854M | 493.367M |
| Property Plant Equipment | - | - | 200.393M | 100.589M | 61.686M |
| Total Current Assets | 478.775M | 584.029M | 940.019M | 1389.854M | 57.175M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 2.661M | 4.487M | 4.648M | 2.619M | 1.458M |
| Net Receivables | 35.921M | 39.437M | 18.504M | 1.822M | 17.686M |
| Long Term Debt | - | - | - | - | 65.018M |
| Inventory | 24.821M | 23.989M | 56.159M | 14.531M | 6.197M |
| Accounts Payable | 46.403M | 68.246M | 122.263M | 17.623M | 5.331M |
| Accumulated Other Comprehensive Income | -0.067M | 1817.148M | 1728.624M | 1334.761M | 472.418M |
| Non Currrent Assets Other | -14.168M | 1.666M | 1.216M | 1.086M | 0.967M |
| Non Current Assets Total | 310.123M | 276.443M | 218.223M | 121.502M | 73.445M |
| Capital Lease Obligations | 41.824M | 42.086M | 28.892M | 55.276M | 14.13M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -93.499M | -127.901M | -1.161M | 28.181M | -4.264M |
| Total Cashflows From Investing Activities | - | -127.901M | -45.274M | 28.181M | -4.264M |
| Total Cash From Financing Activities | 63.173M | 344.964M | 819.833M | 67.979M | -0.112M |
| Net Income | -249.155M | -412.498M | -129.848M | -100.125M | -71.131M |
| Change In Cash | -315.667M | -511.129M | 1291.909M | 9.304M | -78.273M |
| Begin Period Cash Flow | 811.464M | 1322.593M | 30.684M | 21.38M | 99.653M |
| End Period Cash Flow | 495.797M | 811.464M | 1322.593M | 30.684M | 21.38M |
| Total Cash From Operating Activities | -286.177M | -733.128M | 522.403M | -86.963M | -74.11M |
| Depreciation | 23.741M | 15.674M | 10.671M | 7.164M | 3.781M |
| Other Cashflows From Investing Activities | - | - | 3.239M | 2.325M | 2.325M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -47.851M | -227.46M | -8.334M | -3.246M | 0.878M |
| Sale Purchase Of Stock | - | -34.101M | - | - | - |
| Other Cashflows From Financing Activities | 0.91M | 3.186M | 49.86M | 69.889M | -4.264M |
| Capital Expenditures | 93.222M | 127.901M | 47.352M | 12.224M | 14.723M |
| Change In Working Capital | -125.563M | -69.547M | 578.574M | -22.651M | -1.085M |
| Other Non Cash Items | 57.198M | -480.736M | 51.632M | 9.932M | -1.479M |
| Free Cash Flow | -379.399M | -861.029M | 475.051M | -99.187M | -88.833M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Biotechnology ETF | 2 years ago | 670523 |
| 2. | iShares Core MSCI EAFE ETF | 2 years ago | 562943 |
| 3. | BlackRock Health Sciences Opps Inv A | 2 years ago | 412061 |
| 4. | iShares MSCI EAFE Small-Cap ETF | 2 years ago | 348032 |
| 5. | BlackRock Health Sciences Term Trust | 2 years ago | 320123 |
| 6. | State St Gbl Sm Cp Eq ex-US Indx NL Cl A | 2 years ago | 212261 |
| 7. | iShares MSCI EMU Small Cap ETF EUR Acc | 2 years ago | 163214 |
| 8. | iShares Genomics Immnlgy & Hlthcr ETF | 2 years ago | 157840 |
| 9. | Fidelity Nasdaq Composite Index | 2 years ago | 135726 |
| 10. | iShares Nasdaq US Biotech ETF USD Acc | 2 years ago | 116872 |
| 11. | Sigma Inv. House FCP Equity Eurp A Cl | 2 years ago | 113858 |
| 12. | State St Gbl All Cp Eq ex-US Idx NL Cl K | 2 years ago | 96449 |
| 13. | Xtrackers MSCI Eur Small Cap ETF 1C | 2 years ago | 95057 |
| 14. | BlackRock MSCI ACWI ex-U.S. IMI Idx NL F | 2 years ago | 86731 |
| 15. | BlackRock MSCI ACWI ex-U.S. IMI Idx F | 2 years ago | 84342 |
| 16. | CREF Stock R1 | 2 years ago | 83219 |
| 17. | DekaLux-BioTech CF | 2 years ago | 80000 |
| 18. | NT EAFE Small Cap Index Fund - NL | 2 years ago | 74404 |
| 19. | Fidelity Nasdaq Composite ETF | 2 years ago | 73568 |
| 20. | NT Dev Intl SM Idx Fd - NL | 2 years ago | 72014 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Millennium Management LLC | 2 years ago | 2761090 |
| 2. | RA Capital Management, LLC | 2 years ago | 2744270 |
| 3. | BlackRock Inc | 2 years ago | 1805596 |
| 4. | Camber Capital Management LLC | 2 years ago | 1750000 |
| 5. | Bill & Melinda Gates Foundation | 2 years ago | 1597637 |
| 6. | Walleye Trading Advisors, LLC | 2 years ago | 766315 |
| 7. | Goldman Sachs Group Inc | 2 years ago | 739580 |
| 8. | Junked Platinum Investment Management Ltd | 2 years ago | 626684 |
| 9. | Morgan Stanley - Brokerage Accounts | 2 years ago | 531712 |
| 10. | Eversept Partners, LLC | 2 years ago | 496912 |
| 11. | D. E. Shaw & Co LP | 2 years ago | 495780 |
| 12. | NORGES BANK | 2 years ago | 308675 |
| 13. | ExodusPoint Capital Management, LP | 2 years ago | 255164 |
| 14. | Geode Capital Management, LLC | 2 years ago | 202000 |
| 15. | Swiss National Bank | 2 years ago | 198547 |
| 16. | Susquehanna International Group, LLP | 2 years ago | 178172 |
| 17. | UBS Group AG | 2 years ago | 131872 |
| 18. | Credit Suisse First Boston (CSFB) | 2 years ago | 129787 |
| 19. | Vanguard Group Inc | 2 years ago | 125326 |
| 20. | Jump Financial, LLC | 2 years ago | 109500 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...